Objective Residual symptoms of major depressive disorder are a source of long-term
morbidity. New therapeutic strategies are required to alleviate this morbidity and enhance
patient quality of life. Citicoline has been used for vascular accidents and has been effective
in cognitive rehabilitation. It has been used successfully to reduce craving in patients with
substance abuse disorder and for mood management of bipolar disorder. Here, we test
citicoline effectiveness as an adjuvant therapy in major depression. Method A double-blind …